SPY326.54-3.44 -1.04%
DIA265.06-1.53 -0.57%
IXIC10,911.59-274.00 -2.45%

Spero Therapeutics Reports Will Present Data For All Pipeline Programs At IDWeek 2020 Oct. 21-25

Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug

· 10/16/2020 08:35

Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will have 15 data presentations at the Infectious Disease Society of America (IDSA) IDWeek™ 2020 taking place virtually from October 21 - 25, 2020. Presentations will cover each of Spero’s three pipeline programs and include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial that evaluated Spero’s oral antibiotic investigational candidate, tebipenem HBr, for the treatment of adults with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line data from the trial demonstrating that oral tebipenem HBr was statistically non-inferior to intravenous (IV) ertapenem in the treatment of patients with cUTI and patients with AP. Poster presentations include a poster on the Phase 1 clinical trial of SPR720, an oral antimicrobial investigational agent in clinical development by Spero for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. In December 2019, Spero announced positive data from this Phase 1 double-blind, placebo-controlled single ascending dose and multiple ascending dose clinical trial in healthy volunteers.

Presentations pertaining to tebipenem HBr and the epidemiology and management of cUTI:

Title: Oral Tebipenem Pivoxil Hydrobromide is Non-inferior to IV Ertapenem in Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) – Results from the Pivotal ADAPT-PO Study
Presenting Author: Paul Eckburg
Date: Saturday, October 24, 2020
Time: 10:00 – 11:15 AM EDT

Title: Characterization of Tebipenem Pivoxil Hydrobromide Pharmacokinetics-Pharmacodynamics (PK-PD) in a Neutropenic Murine Acute Pyelonephritis (AP) Model
Presenting Author: Brian D. VanScoy
Date: Wednesday, October 21, 2020
Poster Session: PK/PD Studies
Poster Number: 1304

Title: Tebipenem: An Oral Carbapenem with Activity Against Multi-drug Resistant Urinary Tract Infection Isolates of Escherichia coli Collected from US Medical Centers During 2019
Presenting Author: Ian A. Critchley
Date: Wednesday, October 21, 2020
Poster Session: UTIs
Poster Number: 1695

Title: Epidemiology of Complicated Urinary Tract Infections (cUTIs) Presenting in Emergency Departments Across the United States (US)
Presenting Author: Thomas Lodise
Date: Wednesday, October 21, 2020
Poster Session: UTIs
Poster Number: 1673

Title: Hospital Admission Patterns in Adult Patients with Complicated Urinary Tract Infections (cUTIs): Identification of Potentially Avoidable Hospital Admissions Across United States (US) Hospitals
Presenting Author: Thomas Lodise
Date: Wednesday, October 21, 2020
Poster Session: UTIs
Poster Number: 1683

Title: Hospital Costs and Reimbursement in Patients with Resistant Enterobacteriaceae (ENT) Urinary Tract Infection (UTI) in the United States (US): A Multicenter Analysis
Presenting Author: Katherine Sulham
Date: Wednesday, October 21, 2020
Poster Session: UTIs
Poster Number: 1684

Title: Eligibility and Outcomes of Conversion to Oral (PO) Therapy in Patients Hospitalized with Enterobacteriaceae (ENT) Urinary Tract Infection (UTI) in the United States (US): A Multicenter Analysis
Presenting Author: Katherine Sulham
Date: Wednesday, October 21, 2020
Poster Session: UTIs
Poster Number: 1672

Title: Pre- and Post-Hospitalization Resource Utilization and Costs Associated with Urinary Tract Infection (UTI) in both Commercial and Medicare Populations
Presenting Author: Katherine Sulham
Date: Wednesday, October 21, 2020
Poster Session: UTIs
Poster Number: 1691

Title: Health Resource Utilization in Patients with Complicated Urinary Tract Infections (cUTI) and Antibiotic Resistance or Treatment Failure: A Retrospective Database Analysis
Presenting Author: Katherine Sulham
Date: Wednesday, October 21, 2020
Poster Session: UTIs
Poster Number: 1682

Title: Clinical Characteristics and Demographics of Patients with Complicated Urinary Tract Infections (cUTI) and Antibiotic Resistance or Treatment Failure: A Retrospective Database Analysis
Presenting Author: Katherine Sulham
Date: Wednesday, October 21, 2020
Poster Session: UTIs
Poster Number: 1670

Presentations pertaining to SPR720, Spero’s novel investigational oral antibacterial agent that targets enzymes essential for bacterial DNA replication:

Title: Phase 1 First-in-Human Single- and Multiple-Ascending Dose Trial Demonstrates Pharmacokinetics (PK) and Tolerability of SPR720, an Oral DNA GyrB Inhibitor for Mycobacterial Infections
Presenting Author: Angela Talley
Date: Wednesday, October 21, 2020
Poster Session: Novel Agents
Poster Number: 1288

Title: SPR720, A Novel Benzimidazole Gyrase Inhibitor, Demonstrates Potent Efficacy Against Mycobacterium avium ATCC 700898 in a Chronic C3HeBFeJ Mouse Infection Model
Presenting Author: Nicole S. Cotroneo
Date: Wednesday, October 21, 2020
Poster Session: Tuberculosis and other Mycobacterial Infections
Poster Number: 1637

Title: Evaluating the Activity of SPR719, a Novel Aminobenzimidazole, against Nontuberculous Mycobacteria
Presenting Author: Chris Pillar
Date: Wednesday, October 21, 2020
Poster Session: Novel Agents
Poster Number: 1274

Title: Pharmacokinetics/pharmacodynamics of the Novel Gyrase Inhibitor SPR719/SPR720 and Clinical Dose Selection to Treat Pulmonary Mycobacterium avium-complex Disease
Presenting Author: Tawanda Gumbo
Date: Wednesday, October 21, 2020
Poster Session: Tuberculosis and other Mycobacterial Infections
Poster Number: 1659

Presentations pertaining to SPR206, Spero’s next generation polymyxin investigational product candidate being developed to treat multi-drug resistant (MDR) Gram-negative infections in the hospital setting: 

Title: Activity of SPR206, a Polymyxin B derivative, Compared to Colistin Alone and in Combination Against Multidrug-Resistant Pseudomonas aeruginosa Strains
Presenting Author: Jacinda C. Abdul-Mutakabbir
Date: Wednesday, October 21, 2020
Poster Session: PK/PD studies
Poster Number: 1295

Abstracts are accessible via the IDWeek™ website. Poster presentations may be accessed through Spero Therapeutics’ website on the “Key Publications and Presentations” page under the “Pipeline” tab following their completion.